Imagion poised to accelerate Magsense progress
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Through the filing of a Pre-Submission with the U.S. Food and Drug Administration (FDA), MedTech company Imagion Biosystems (ASX:IBX) has taken its first step towards gaining approval to commence its first-in-human study into its non-invasive, non-radioactive imaging technology MagSense, for staging HER2 breast cancer.
This comes only weeks after Imagion’s MagSense Systems gained “Breakthrough Device” designation from the FDA, a factor that will help expedite communication between the company and the FDA for this approval process.
To qualify for Breakthrough Device status a product must be considered to “provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions”.
Achieving Breakthrough Device status in itself was a major development that resulted in Imagion’s shares increasing more than 150% under record volumes.
FDA status paves way for accelerated communications
Based on FDA’s previous guidance, the company has filed a Pre-Submission with the agency in anticipation of filing for an investigational device exemption (IDE), a US regulatory requirement for human studies with medical devices.
In the submission, Imagion has requested a “sprint” discussion, a facility within the Breakthrough Device program intended to expedite communication.
“The recent Breakthrough Device designation by the FDA has been very timely, allowing us to request an expedited review of our submission” said Bob Proulx, executive chairman.
Proulx went on to explain that while the designation does not change the compliance requirements, it should improve the speed with which the company receives feedback from the agency, as well as reducing the risk of disruptions to its plans for undertaking a first-in-human study.
Following a brief review of the Pre-Submission by the FDA, Imagion will be able to schedule a meeting wherein both the reviewers within the agency and the company can address specific questions related to the IDE.
The company’s early feasibility, first-in-human study is a critical milestone in the development of the company’s non-radioactive imaging technology which provides a non-surgical solution to identify the progression or stage of HER2 breast cancer metastases.
The MagSense test for the staging of HER2 breast cancer aims to eliminate the unnecessary surgeries and concomitant morbidity resulting from the current standard of care biopsy procedure.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
